FTSE MIB
33.785,30 +38,64 (+0,11%) Dow Jones
37.903,29 +87,37 (+0,23%) Nasdaq
15.605,48 -52,34 (-0,33%) Nikkei 225
38.236,07 -37,98 (-0,10%) Petrolio
79,70 +0,70 (+0,89%) Bitcoin EUR
54.749,56 +811,83 (+1,51%)
Genelux Corporation (GNLX)
Dopo ore:
| Chiusura precedente | 3,1100 |
| Aperto | 3,1300 |
| Denaro | 3,2500 x 200 |
| Lettera | 3,3000 x 200 |
| Min-Max giorno | 3,1300 - 3,3500 |
| Intervallo di 52 settimane | 3,0600 - 40,9800 |
| Volume | |
| Media Volume | 142.526 |
| Capitalizzazione | 88,119M |
| Beta (5 anni mensile) | N/D |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,1600 |
| Prossima data utili | N/D |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 26,00 |
GlobeNewswireGenelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WESTLAKE VILLAGE, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that on September 11, 2023, the Company’s Board of Directors (the “Board”) granted inducement awards consisting of non-qualified stock options to purchase 444,300 shares of common stock to seven new employees under the Company’s 2023 Inducement Plan, including an option to purchase 150,000 shares of common stock to Lourie Zak, the Company
- GlobeNewswire
Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference
WESTLAKE VILLAGE, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, Chairman and CEO, will present a corporate overview with institutional investors during the H.C. Wainwright 25th Annual Global Investment Conference held the week of September 11th, 2023. The Company will also attend virtual one-on-one meetings during the conference. Institutional investors interested in a
- GlobeNewswire
Genelux Corporation Announces New Chief Financial Officer
WESTLAKE VILLAGE, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Lourie S. Zak will join the company as Chief Financial Officer, effective August 28, 2023. "I am excited to welcome Lourie to Genelux as our new Chief Financial Officer," said Thomas Zindrick, President, Chairman and CEO of Genelux. "Lourie’s extensive experience in finance and healthcare advisory will be incredibly helpful as we cont
